📰 Altimmune News
Page 2 - Altimmune News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Altimmune. Real-time updates on events, politics, business and more.
March 10, 2024
GSA Capital Partners LLP raised its stake in Altimmune, Inc. (NASDAQ:ALT – Free Report) by 153.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 445,868 shares of the company’s stock after purchasing an additional 269,676 shares during the quarter. GSA Capital […]
February 24, 2024
NEW YORK, Feb. 24, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities...
February 19, 2024
NEW YORK, Feb. 19, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities...
February 14, 2024
B. Riley reissued their buy rating on shares of Altimmune (NASDAQ:ALT – Free Report) in a research note released on Tuesday morning, Benzinga reports. They currently have a $20.00 target price on the stock. A number of other brokerages have also weighed in on ALT. The Goldman Sachs Group started coverage on shares of Altimmune […]
February 13, 2024
WealthPlan Investment Management LLC purchased a new position in Altimmune, Inc. (NASDAQ:ALT – Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 11,931 shares of the company’s stock, valued at approximately $31,000. A number of other institutional investors and hedge funds also […]
February 8, 2024
Altimmune, Inc. (NASDAQ:ALT – Get Free Report) was up 5.8% during trading on Tuesday . The company traded as high as $10.06 and last traded at $9.93. Approximately 926,426 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 6,349,605 shares. The stock had previously closed at $9.39. Wall […]
January 27, 2024
Altimmune, Inc. (NASDAQ:ALT – Get Free Report)’s stock price fell 4.1% during trading on Wednesday . The company traded as low as $9.48 and last traded at $9.61. 1,232,811 shares changed hands during mid-day trading, a decline of 84% from the average session volume of 7,909,166 shares. The stock had previously closed at $10.02. Wall […]
January 27, 2024
The Goldman Sachs Group assumed coverage on shares of Altimmune (NASDAQ:ALT – Free Report) in a report released on Wednesday, MarketBeat reports. The brokerage issued a neutral rating and a $13.00 price target on the stock. ALT has been the topic of a number of other research reports. HC Wainwright restated a buy rating and […]
January 24, 2024
Altimmune, Inc. (NASDAQ:ALT – Free Report) – Research analysts at HC Wainwright issued their FY2028 EPS estimates for shares of Altimmune in a report released on Friday, January 19th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings per share of $0.26 for the year. HC Wainwright currently has a “Buy” rating […]
January 24, 2024
Altimmune, Inc. (NASDAQ:ALT – Free Report) – Stock analysts at HC Wainwright issued their FY2028 EPS estimates for shares of Altimmune in a note issued to investors on Friday, January 19th. HC Wainwright analyst P. Trucchio expects that the company will post earnings of $0.26 per share for the year. HC Wainwright currently has a […]